^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CIMAbior (rituximab biosimilar)

i
Other names: 1B8
Associations
Trials
Company:
Center of Molecular Immunology
Drug class:
CD20 inhibitor
Related drugs:
Associations
Trials
almost2years
Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy. (PubMed, Front Immunol)
The anti-CD20 antibody rituximab (RTX) has substantially improved outcomes of patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing lymphomas. Anti-CD20-IL2no-alpha (hIgG1) strongly expanded NK and CD8+ T cells but not Tregs in tumor-bearing mice. These findings suggest that anti-CD20-IL2no-alpha could represent an alternative treatment for B cell lymphoma patients, mainly those refractory to RTX therapy.
Journal • Immunomodulating
|
CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha)
|
CD20 expression • IL2RA expression
|
Rituxan (rituximab) • CIMAbior (rituximab biosimilar)